Beta Blockade in Critical Injury

Stopped early · Phase 2

Conditions studied: Trauma

In brief

Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.

Key facts

Study ID

NCT00356187

Run by

Denver Health and Hospital Authority

People needed

15

Starts

2006-02-15

Expected to finish

2009-01-31

Last updated by the study team

2018-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ISS>25, stable at 48 hours after injury
• Fully resuscitated
• Ventilated
• Exclusion Criteria Include:
• Intracranial hypertension requiring active treatment
• Hypotension/Pressors
• Already on beta blocker for a standard indication

Where it is running

• Denver Health Medical Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.